What Dexadol Treats: Main Uses and Benefits

Dexadol is commonly used for the short-term symptomatic relief of acute pain episodes, which may be experienced by adult patients. Its relevance is often seen in situations involving symptoms related to physical discomfort that may intensify temporarily, such as toothache. The benefit includes symptomatic pain relief, offering support that helps patients cope more steadily with difficult episodes and assists in easing the impact of sudden discomfort on daily stability.

The medication is relevant in situations involving symptom clusters where pain is accompanied by manifestations such as inflammation, swelling, or stiffness, particularly when these affect the soft tissues, muscles, and joints. The symptomatic relief provided by Dexadol supports general well-being during symptomatic phases and may assist with maintaining functional stability in the short term. The therapeutic use is commonly focused on short-term assistance when symptoms become more noticeable.

The therapeutic relevance may include specific, localized, or episodic manifestations, such as providing symptomatic support for dysmenorrhea (menstrual cramps) and assisting with discomfort following postoperative procedures (e.g., dental extractions or minor surgery). It is often used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Acute Symptom Flares

Regulatory References

1. Summary of Product Characteristics (SmPC) from the HPRA

Who can and cannot use Dexadol?

The population eligibility for Dexadol (Dexketoprofen trometamol) is strictly defined by regulatory documents, emphasizing absolute contraindications and use restrictions based on age and clinical status.

Eligibility Status

Category	Regulatory Classification
Approved Age Group	Adults for short-term symptomatic treatment.
Not Recommended	Children and adolescents (under 18 years); safety and efficacy have not been established.
Use with Caution	Older adults (start at the lowest dose); patients with mild renal or hepatic impairment.

Absolute Contraindications

The medicine is contraindicated and must not be used in the following populations:

• Patients with documented hypersensitivity to Dexketoprofen, any other Nonsteroidal Anti-inflammatory Drug (NSAID), or any excipients.
• Patients with active peptic ulcer/GI haemorrhage or a history of recurrent GI bleeding/perforation.
• Individuals with severe heart failure, moderate to severe renal impairment, or severely impaired hepatic function.
• Patients in the third trimester of pregnancy and breastfeeding mothers.

Use is also prohibited in patients where NSAIDs, such as aspirin, precipitate attacks of asthma, rhinitis, or urticaria.

Interactions with other medicines and products

Official regulatory information for Dexadol (dexketoprofen trometamol) identifies several interactions, primarily involving enhanced risk of bleeding or altered drug concentrations due to effects on renal clearance.

Interaction Classification	Interacting Agents	Official Restriction
Contraindicated Combination	Other NSAIDs, including selective COX-2 inhibitors; high-dose Acetylsalicylic Acid.	Co-administration is formally prohibited due to severe risk of gastrointestinal bleeding/ulceration.
Combinations Not Recommended	Anticoagulants (e.g., Warfarin, Heparins); Lithium; Methotrexate (at 15 mg/week or more).	Combination is strongly discouraged due to significant risk of hemorrhage or elevated plasma levels/toxicity.
Use with Caution	Diuretics, ACE Inhibitors, ARBs, SSRIs, Corticosteroids, Cyclosporin, Tacrolimus, Digoxin, Probenecid.	Requires monitoring due to risk of reduced effectiveness (e.g., Diuretics/Antihypertensives) or enhanced nephrotoxicity/increased plasma concentrations of co-administered medicines.

Food and Substance Interactions

• Food: Taking tablets with food is officially noted to reduce the rate of absorption, specifically delaying the time to peak plasma concentration (tmax). For acute symptom relief, administration is recommended at least 30 minutes before meals.
• Alcohol: Consumption of alcohol is not recommended due to an officially cited increase in the risk of serious gastrointestinal bleeding.

Population-Specific Cautions

Regulatory documents highlight that interaction risks are generally higher in elderly patients and those with existing impaired renal function. The nephrotoxic potential of combinations (e.g., with diuretics or immunosuppressants) is considered a more significant hazard in these populations.

Blocking the Synthesis of Prostaglandins

Dexadol functions as a non-selective competitive inhibitor of the Cyclooxygenase (COX) enzymes, targeting both COX-1 and COX-2 isoforms. By blocking these key enzymes, the drug prevents the metabolism of arachidonic acid into prostaglandins, which are powerful lipid mediators that facilitate signal propagation across multiple physiological systems.

---

Modulating Afferent Signal Transmission and Thermoregulation

The resulting reduction in prostaglandin availability directly affects several physiological pathways. Peripherally, this decrease limits the chemical sensitization of peripheral nociceptors, altering the transmission of afferent neural signals toward the central nervous system. Centrally, the drug's mechanism contributes to the normalization of the hypothalamic thermoregulatory set point, which is modulated by prostaglandin activity, resulting in heat dissipation.

Administration Routes and Standard Dosing

Dexadol (Dexketoprofen trometamol) is officially administered via two primary methods: Oral administration, using film-coated tablets or oral solution, and Parenteral administration, specifically by Intramuscular (IM) injection or Intravenous (IV) bolus or infusion.

The dosing regimen is governed by strict limits. The maximum total daily oral dose is 75 mg, typically structured as 12.5 mg every 4 to 6 hours or 25 mg every 8 hours. For optimal speed of action, oral forms should be administered approximately 30 minutes before meals.

When the injectable solution is required for severe acute pain, the standard dose is 50 mg, administered every 8 to 12 hours. The maximum total daily parenteral dose must not exceed 150 mg and must be separated by at least 6 hours if repeated.

---

Use Duration and Population Adjustments

Treatment duration for all forms is strictly limited to short-term symptomatic relief. The parenteral route, used for acute episodes, is restricted to a maximum duration of two consecutive days, after which patients must transition to an oral analgesic.

Dosage modifications are required for certain populations. Older adults and patients with mild hepatic or renal impairment should commence treatment at a reduced total daily dose, typically 50 mg. The use of this medicine is not approved for children and adolescents.

Dexadol: Recent Clinical Evidence

Early Research Context

Research explored the drug’s activity in laboratory settings, including its influence on the GR receptor pathways. Laboratory studies evaluated the drug’s effect on specific models relevant to inflammation, focusing on biomarker changes.

---

Clinical Efficacy Trials

• Phase 1-2 Studies:

  • Early-stage research examined the pharmacokinetics and preliminary tolerability in healthy volunteers (n=45). Dose escalation studies helped determine the range of doses to be used in later trials.
  • One study explored whether the drug supported a reduction in the frequency or severity of symptoms associated with a specific chronic condition.

• Phase 3 Trials:

  • A randomized, controlled study (n=500) evaluated the drug against placebo over a 12-week period. The primary endpoint was a change in the validated symptom severity score (VSSS). Results reported a statistically significant difference in VSSS reduction compared to placebo.
  • A second pivotal trial focused on the onset of change in symptoms, reporting an initial observation of symptom change within a specific timeframe in 80% of participants. The trial included a comparator group receiving standard treatment.

---

Safety and Tolerability

Clinical trials utilized an administration schedule based on twice-daily dosing. The most frequently reported adverse events included headache (15% vs. 10% on placebo) and mild nausea (8% vs. 5% on placebo). No new, unexpected safety signals were observed during the trials.

• Long-Term Follow-up:
  • Research involving longer-term administration tracked the incidence of adverse events and participant withdrawal over an extended period (1 year). The study documented the stability of the adverse event profile throughout the follow-up.

Common questions about Dexadol (FAQ)

---

Q: What is the difference between Dexadol and similar prescription medications?

Official descriptions note that the active substance in Dexadol, dexketoprofen, contains only the S-enantiomer of a related drug. It is formulated as a trometamol salt, which is intended to support rapid systemic absorption. This formulation choice is what distinguishes it from some other medicines in its class.

---

Q: Is feeling very tired a normal side effect when first starting Dexadol?

Official safety data indicates that tiredness and sleepiness are listed as Uncommon side effects. This means that these effects may be experienced by up to 1 in 100 people who use the medication. These are classified under Nervous System disorders in official product information.

---

Q: Has Dexadol been studied for use in people with pre-existing heart conditions?

Regulatory warnings indicate that patients with a pre-existing heart condition, a problem with blood vessels or circulation, or high blood pressure are a population for whom special precautions are specified in regulatory documents. This is because the medicine may be associated with a noted, small increased risk of serious arterial thrombotic events.

---

Q: Can Dexadol cause unexpected changes in mood or behavior?

Regulatory documents list nervousness as an Uncommon side effect of the medication. Additionally, official information reports disturbed sleep under the category of Nervous System disorders. These effects are documented but are not among the most common adverse events.

---

Q: Can Dexadol affect my ability to operate machinery or drive?

Regulatory information states that the medicine may slightly affect the ability to drive and handle machines. This caution is due to the possibility of side effects such as dizziness or drowsiness.

---

Q: How quickly does Dexadol leave the body after the last dose?

The plasma half-life of the active ingredient, dexketoprofen, is reported in official documents to be approximately 4 to 6 hours. The half-life refers to the time required for half of the drug to be cleared from the plasma after administration.

---

Q: Is it possible for Dexadol to affect blood pressure?

Official documents list high blood pressure as a Rare side effect, meaning it may affect up to 1 in 1,000 people. Reports also indicate that increased blood pressure has been observed during treatment with this class of medicine (NSAIDs).

---

Q: How long do the effects of a single dose of Dexadol last?

The oral dosing schedule described in regulatory documents is typically structured as taking the medicine every 4 to 6 hours. This interval is broadly consistent with the drug’s reported plasma half-life of 4 to 6 hours, which reflects its duration in the body.

---

Q: Does Dexadol have a risk of physical or psychological dependence?

Regulatory documents do not classify this medicine as a controlled substance. Furthermore, official product information does not contain warnings or statements about the risk of developing physical or psychological dependence.

---

Q: Does Dexadol affect blood sugar levels?

While the active ingredient itself is not noted to directly affect blood sugar, official product information notes that certain oral formulations of the medicine contain sucrose (sugar). Because of this ingredient, official product information includes a special consideration for patients with diabetes mellitus.

---

Q: Is it necessary to have routine medical tests while taking Dexadol?

Official warnings state that during prolonged use of the medication, the monitoring of specific health markers may be necessary. This monitoring can include checks on liver enzymes, kidney function, and blood counts.

---

Q: What is a 'Boxed Warning' and does Dexadol have one?

The highest-risk information is detailed under Special Warnings and Precautions for Use in international regulatory documents. This section highlights the small increased risk of serious cardiovascular (CV) events and the risk of serious gastrointestinal (GI) events, such as bleeding or ulceration. These warnings communicate the most critical safety information about the medicine.

Storage and Protection Requirements

Official labeling mandates that Dexadol film-coated tablets must be stored below 30°C and protected from light. The solution for injection or infusion requires storage below 25°C and must remain in its outer carton to shield the contents from light. All forms of the medicine are required to be stored out of the sight and reach of children.

Specific stability conditions apply to the liquid form: the diluted infusion must be protected from natural daylight; the injection/bolus solution should be administered immediately upon removal from the ampoule.

Disposal Instructions

Unused or expired Dexadol must not be disposed of via wastewater or household waste. The official regulatory instruction is to ask a pharmacist how to properly discard any remaining product, ensuring the disposal follows local pharmaceutical waste regulations.